Loading...

Purified anti-human CD16 Antibody

Pricing & Availability
Clone
3G8 (See other available formats)
Regulatory Status
RUO
Workshop
V NK80
Other Names
FcγRIII, Fc gamma receptor, Fc gamma receptor 3
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
3G8_Pure_071805
Human peripheral blood lymphocytes stained with purified 3G8 and anti-mouse IgGs FITC
  • 3G8_Pure_071805
    Human peripheral blood lymphocytes stained with purified 3G8 and anti-mouse IgGs FITC
Cat # Size Price Quantity Check Availability Save
302001 25 µg 52€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
302002 100 µg 88€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD16 is known as low affinity IgG receptor III (FcγRIII). It is expressed as two distinct forms (CD16a and CD16b). CD16a (FcγRIIIA) is a 50-65 kD polypeptide-anchored transmembrane protein. It is expressed on the surface of NK cells, activated monocytes, macrophages, and placental trophoblasts in humans. CD16b (FcγRIIIB) is a 48 kD glycosylphosphatidylinositol (GPI)-anchored protein. Its extracellular domain is over 95% homologous to that of CD16a, and it is expressed specifically on neutrophils. CD16 binds aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC).

Product Details
Technical data sheet

Product Details

Reactivity
Human,Cynomolgus,Rhesus
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Human PMN cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/mL
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
CyTOF® - Verified
Block, IHC-F, IP, Stim - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 2.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The 3G8 antibody clone blocks neutrophil phagocytosis and stimulates NK cell proliferation. It has been reported that this clone interacts with the FcγRIIa and FcγRIIIb receptors causing neutrophil activation and aggregation18. Due to this phenomenon staining in whole blood may cause a reduction in the number of granulocytes or alter their scatter profile.

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections6, immunoprecipitation3, stimulation of NK cell proliferation4, blocking of phagocytosis5, and blocking of immunoglobulin binding to FcγRIII7,8. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 302049, 302050, 302057, 302058).

Application References

(PubMed link indicates BioLegend citation)
  1. Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  3. Edberg J, et al. 1997. J. Immunol. 159:3849. (IP)
  4. Hoshino S, et al. 1991. Blood 78:3232. (Stim)
  5. Tamm A, et al. 1996. Immunol. 157:1576. (Block)
  6. Da Silva DM, et al. 2001. Int. Immunol. 13:633. (IHC)
  7. Holl V, et al. 2004. J. Immunol. 173:6274. (Block)
  8. Hober D, et al. 2002. J. Gen. Virol. 83:2169. (Block)
  9. Brainard DM, et al. 2009. J. Virol. 83:7305. PubMed
  10. Smed-Sörensen A, et al. 2008. Blood 111:5037. (Block) PubMed
  11. Timmerman KL, et al. 2008. J. Leukoc. Biol. 84:1271. (FC) PubMed
  12. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  13. Rout N, et al. 2010. PLoS One 5:e9787. (FC)
  14. Kim WK, et al. 2006. Am. J. Pathol. 168:822. (FC)
  15. Boltz A, et al. 2011. J. Biol Chem. 286:21896. PubMed
  16. Wu Z, et al. 2013. J. Virol. 87:7717. PubMed
  17. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
  18. Vossebeld PJ, et al. 1997. Biochem J. 323:87-94 (Stim)
Product Citations
  1. Prodjinotho UF, et al. 2017. PLoS Negl Trop Dis. 11:e0005777. PubMed
  2. Winkler M, et al. 2017. PLoS One.. 10.1371/journal.pone.0182427. PubMed
  3. Santos R, et al. 2017. Nat Commun. . 10.1038/s41467-017-01760-5. PubMed
  4. Chevrier S, et al. 2018. Cell Syst. 0.675. PubMed
  5. Sibener LV et al. 2018. Cell. 174(3):672-687 . PubMed
  6. Olin A, et al. 2018. Cell. 174:1277. PubMed
  7. Wagner J et al. 2019. Cell. 177(5):1330-1345 . PubMed
  8. Dutertre CA, et al. 2020. Immunity. 51(3):573-589.e8.. PubMed
  9. Li L, et al. 2019. Cell Stem Cell. 24:271. PubMed
  10. Lavin Y et al. 2017. Cell. 169(4):750-765 . PubMed
  11. Urlaub D, et al. 2017. J Immunol. 198:1944. PubMed
  12. Dallari S, et al. 2017. Nat Commun. 8:14830. PubMed
  13. Fasbender F, et al. 2017. Front Immunol. 0.88125. PubMed
  14. Miyamoto DT, et al. 2018. Cancer Discov. 0.533333333. PubMed
  15. Cao Q, et al. 2018. Am J Physiol Renal Physiol. 314:F561. PubMed
  16. Zhong Q, et al. 2018. J Immunol. 200:3913. PubMed
  17. Eldredge LC, et al. 2019. Am J Physiol Lung Cell Mol Physiol. 317:L49. PubMed
  18. Steffen U, et al. 2020. Nat Commun. 0.541666667. PubMed
  19. Eccles JD, et al. 2020. Cell Rep. 30:351. PubMed
  20. Jog NR, et al. 2018. Front Immunol. 9:2198. PubMed
  21. Auladell M, et al. 2019. Clin Transl Immunology. 8:e01090. PubMed
  22. Frobel J, et al. 2018. Clin Epigenetics. 10:67. PubMed
  23. Ardain A, et al. 2019. Nature. 570:528. PubMed
  24. Boutboul D, et al. 2018. J Clin Invest. 128:3071. PubMed
  25. Ravindran A, et al. 2018. Front Immunol. 9:2193. PubMed
  26. Lakshmikanth T, et al. 2020. Cell Reports. 32(3):107923. PubMed
  27. Park JE, et al. 2020. Journal for ImmunoTherapy of Cancer. 8(2):e000873.. PubMed
  28. Pohl K, et al. 2018. PLoS One. 13:e0209026. PubMed
  29. Sung JA, et al. 2018. Mol Ther. 26:2496. PubMed
  30. Gainers M, et al. 2007. J Immunol. 179:8509. PubMed
  31. Mody P, et al. 2007. Blood. 110:2974. PubMed
  32. Smed-Sörensen A, et al. 2008. Blood. 111:5037. PubMed
  33. Boltz A, et al. 2011. J Biol Chem. 286:21896. PubMed
  34. Edri-Brami M, et al. 2012. PLoS One. 7:e35772. PubMed
  35. Wu Z, et al. 2013. J Virol. 87:7717. PubMed
  36. Chevrier S, et al. 2021. Cell Reports Medicine. 2(1):100166. PubMed
  37. Okubo K, et al. 2021. Cell Reports. 35(7):109142. PubMed
  38. Martin E, et al. 2020. JCI Insight. :5. PubMed
  39. Mann ER, et al. 2020. Sci Immunol. :5. PubMed
  40. De Maeyer RPH, et al. 2020. Nat Immunol. 21:615. PubMed
  41. Combes AJ, et al. 2021. Nature. 591:124. PubMed
  42. Doni A, et al. 2021. Nat Commun. 12:3739. PubMed
  43. Korn MA, et al. 2020. J Immunol. 205:2595. PubMed
  44. Ehinger E, et al. 2021. Cardiovasc Res. 117:1166. PubMed
  45. Kato M, et al. 2021. PLoS One. 16:e0252116. PubMed
  46. Syrimi E, et al. 2021. iScience. 24:103215. PubMed
  47. Holder KA, et al. 2021. Clin Transl Immunology. 10:e1348. PubMed
  48. Park YJ, et al. 2022. PLoS Pathog. 18:e1010468. PubMed
  49. Mask E, et al. 2022. Front Cell Infect Microbiol. 12:880860. PubMed
  50. Farhadian SF, et al. 2022. JCI Insight. 7:. PubMed
  51. Shemesh A, et al. 2022. J Exp Med. 219:. PubMed
  52. Ravell JC, et al. 2020. J Clin Invest. 130:507. PubMed
  53. Weinhage T, et al. 2020. J Immunol. 205:56. PubMed
  54. Farrington LA, et al. 2020. PLoS Pathog. 16:e1008997. PubMed
  55. Li J, et al. 2021. Haematologica. 106:3115. PubMed
  56. Friedman D, et al. 2021. J Cell Sci. 134:. PubMed
  57. Alcántara-Hernández M, et al. 2021. Nat Protoc. 16:4855. PubMed
  58. Dorsch M, et al. 2020. Eur J Immunol. 50:656. PubMed
  59. Alpert A, et al. 2022. Cell Syst. 13:71. PubMed
  60. McCarthy EE, et al. 2022. Cell Rep. 39:110815. PubMed
  61. Shemesh A, et al. 2022. J Exp Med. 219: . PubMed
  62. Kirolos SA, et al. 2022. J Leukoc Biol. 112:1399. PubMed
RRID
AB_314201 (BioLegend Cat. No. 302001)
AB_314202 (BioLegend Cat. No. 302002)

Antigen Details

Structure
Ig superfamily, transmembrane form (50-65 kD) or GPI-linked form (48 kD)
Distribution

NK cells, activated monocytes, macrophages, neutrophils

Function
Low affinity IgG Fc receptor, phagocytosis, ADCC
Ligand/Receptor
Aggregated IgG, IgG-antigen complex
Cell Type
Dendritic cells, Macrophages, Monocytes, Neutrophils, NK cells
Biology Area
Immunology, Innate Immunity
Molecular Family
CD Molecules, Fc Receptors
Antigen References

1. Fleit H, et al. 1982. P. Natl. Acad. Sci. USA 79:3275.
2. Stroncek D, et al. 1991. Blood 77:1572.
3. Wirthmueller U, et al. 1992. J. Exp. Med. 175:1381.

Gene ID
2214 View all products for this Gene ID
UniProt
View information about CD16 on UniProt.org

Related FAQs

Is our human Trustain FcX™ (cat# 422302) compatible with anti human CD16, CD32 and CD64 clones 3G8, FUN-2 and 10.1 respectively?

Yes

Go To Top Version: 4    Revision Date: 08.22.2022

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account